Clinical Data for New Boston Scientific Stents Highlighted at TCT
September 14, 2010 – The latest clinical trial data for the Promus Element and Taxus Element coronary stents will be released during the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Sept. 21–25, in Washington, D.C.
“We look forward to the presentation of data from the PLATINUM QCA trial and the PERSEUS clinical program, which support the performance of our two platinum chromium drug-eluting stent platforms – Promus Element and Taxus Element,” said Keith D. Dawkins, M.D., senior vice president and chief medical officer for Boston Scientific’s cardiology, rhythm and vascular group. “Our Promus Element everolimus-eluting stent system and Taxus Element paclitaxel-eluting stent system continue to be well received by European physicians, and we are looking forward to U.S. approval. We also anticipate positive data from the Taxus ATLAS trials, assessing the long-term performance of our Taxus Liberté stents in patients with workhorse and complex lesions.”
Schedule of Events (All times are eastern time; all events are held at the Walter E. Washington Convention Center.)
Tuesday, Sept. 21
• Promus Element Stent Clinical and Angiographic Outcomes. Ian T. Meredith, M.D., co-principal investigator of the PLATINUM clinical program, will present 30-day clinical outcomes and nine-month qualitative coronary angiography (QCA) and intravascular ultrasound (IVUS) data from the PLATINUM QCA study in a podium session at 4:19 p.m. during the Drug-Eluting Stent Summit in ballroom C. The PLATINUM clinical program includes five separate multicenter studies designed to assess the safety and efficacy of the Promus Element stent.
• SYNTAX Study Data. Patrick W. Serruys, M.D., Ph.D., and Friedrich W. Mohr, M.D., Ph.D., will present analyses of three-year follow-up data from the landmark SYNTAX clinical trial assessing optimal revascularization strategies in patients with left main disease and three-vessel disease. Both analyses will be presented in a featured clinical research session 6–8 p.m. in room 208AB. SYNTAX is the first randomized, controlled clinical trial comparing percutaneous coronary intervention using drug-eluting stents to coronary artery bypass graft surgery in patients with left main and/or three-vessel disease.
Wednesday, Sept. 22
• Taxus Element (ION) Stent Diabetic Study. Louis A. Cannon, M.D., co-principal investigator of the PERSEUS clinical program, will present 12-month data from the PERSEUS Diabetic study in a poster session 1-3:30 p.m. on the lower level. Results will assess the benefit of the Taxus Element in patients with and without diabetes.
• Taxus ATLAS studies. Mark A. Turco, M.D., co-principal investigator of the Taxus ATLAS trials, will present five-year data from the workhorse trial and four-year data from the long lesion trial. John A. Ormiston, M.D., will present four-year data from the Taxus ATLAS small vessel trial in a series of poster sessions 1–3:30 p.m. on the lower level. Results will assess the long-term benefit of the Taxus Liberté stent in workhorse lesions, the Taxus Liberté Long 38 mm stent in long lesions and the Taxus Liberté Atom 2.25 mm stent in small vessels. The company plans to issue a press release at this time.
• Boston Scientific Symposium on Innovation. The company will sponsor a symposium titled “Pushing the Boundaries of Technology & Innovation,” 8–9:30 p.m. in the Grand Ballroom of the Renaissance Hotel. The symposium will feature presentations by Martin B. Leon, M.D., of the Cardiovascular Research Foundation, titled “Making More Possible for More Patients Through Innovations,” and by Steve Wozniak, co-founder of Apple Computer, titled “Defining Tomorrow’s Innovation.” A reception will be held prior to the symposium, beginning at 7 p.m.
Thursday, Sept. 23
• Promus and Taxus Express Stents. Gregg W. Stone, M.D., will present two-year results from the SPIRIT IV Clinical Trial at 11:24 a.m., during a Late-Breaking Trials session in the main arena. SPIRIT IV is a prospective, single-blinded, multicenter clinical trial with 3,690 patients randomized 2:1 to the Xience V stent (also sold under name Promus) or the Taxus Express Stent. The Taxus Express is a first-generation drug-eluting stent that has been replaced by the thin-strut Taxus Liberté stent and more recently by the platinum chromium Taxus Element stent.
Saturday, Sept. 25
• HORIZONS-AMI Three-Year Data. Stone will present three-year data from the HORIZONS-AMI Clinical Trial at 11:24 a.m., during a Late-Breaking Trials session in the main arena. HORIZONS-AMI is a randomized, controlled clinical trial designed to compare Taxus stents to bare-metal stents in 3,400 acute myocardial infarction patients. The company plans to issue a press release at this time.
Boston Scientific will present its latest cardiology, rhythm and vascular products at booth 1443 in the exhibit hall.
For more information: www.bostonscientific.com
More like this
- Boston Scientific Highlights TAXUS, PROMUS Clinical Data at TCT 2009
- Next-Generation Stent Trial Enrollment Begins in China
- Boston Scientific Launches Promus Element Stent in China
- Boston Scientific Data Backs Safety of Taxus
- Boston Scientific Completes Enrollment in Pivotal Trial for New Everolimus Stent